BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borah P, Deka S, Mailavaram RP, Deb PK. P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future. Curr Pharm Des 2019;25:2792-807. [PMID: 31333097 DOI: 10.2174/1381612825666190716111245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 IJzerman AP, Jacobson KA, Müller CE, Cronstein BN, Cunha RA. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. Pharmacol Rev 2022;74:340-72. [PMID: 35302044 DOI: 10.1124/pharmrev.121.000445] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
2 Campos-Martins A, Bragança B, Correia-de-Sá P, Fontes-Sousa AP. Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction. Front Pharmacol 2021;12:724320. [PMID: 34489711 DOI: 10.3389/fphar.2021.724320] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Domenici MR, Mallozzi C, Pepponi R, Casella I, Chiodi V, Ferrante A, Popoli P. Insight into the Role of the STriatal-Enriched Protein Tyrosine Phosphatase (STEP) in A2A Receptor-Mediated Effects in the Central Nervous System. Front Pharmacol 2021;12:647742. [PMID: 33953681 DOI: 10.3389/fphar.2021.647742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Catarzi D, Varano F, Colotta V. Special Issue "Adenosine Receptors as Attractive Targets in Human Diseases". Pharmaceuticals (Basel) 2021;14:140. [PMID: 33578687 DOI: 10.3390/ph14020140] [Reference Citation Analysis]
5 Borah P, Hazarika S, Deka S, Venugopala KN, Nair AB, Attimarad M, Sreeharsha N, Mailavaram RP. Application of Advanced Technologies in Natural Product Research: A Review with Special Emphasis on ADMET Profiling. Curr Drug Metab 2020;21:751-67. [PMID: 32664837 DOI: 10.2174/1389200221666200714144911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
6 Menéndez Méndez A, Smith J, Engel T. Neonatal Seizures and Purinergic Signalling. Int J Mol Sci 2020;21:E7832. [PMID: 33105750 DOI: 10.3390/ijms21217832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wernly B, Zhou 周稚超 Z. More purinergic receptors deserve attention as therapeutic targets for the treatment of cardiovascular disease. Am J Physiol Heart Circ Physiol 2020;319:H723-9. [PMID: 32822211 DOI: 10.1152/ajpheart.00417.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Deb PK. Therapeutic Potentials of Adenosine Receptors: The State of The Art. Curr Pharm Des 2019;25:2789-91. [PMID: 31674891 DOI: 10.2174/138161282526191007143942] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]